Skip to main content

Why Prescribe the CeQur Simplicity Wearable Insulin Patch?

Patients that use the CeQur Simplicity wearable insulin patch are more likely to adhere to their insulin regimen and achieve glycemic targets.

CeQur Simplicity is revolutionizing mealtime insulin delivery for T1 and T2 diabetes patients on multiple daily injections (MDIs). Our 3-day wearable insulin patch removes mealtime insulin barriers, providing a convenient, discreet, and injection-free way for people with diabetes to deliver mealtime and correction boluses.4


Can be worn for up to three days5


Holds up to 200 units of rapid-acting insulin1

Easy to use and learn, <30 minutes of training1


Can be worn and dosed under clothing

One click administers two units of insulin 

Thin (<4 stacked quarters), compact (65 x 36 mm), and lightweight (10 gm)


Less pain encourages adherence3

Clinically shown to reduce A1C, increase TIR1

One patch replaces nine mealtime injections

Small, flexible cannula for painless insulin delivery5

The CeQur Simplicity wearable insulin patch is intended for subcutaneous, bolus delivery of insulin for the management of diabetes mellitus in adults over 21 years of age requiring insulin. The patch is not intended for pediatric patients and does not replace the need for basal insulin.

CeQur Simplicity Is Easy to Teach and Use

Getting patients started with CeQur Simplicity is easy. Most patients need <30 minutes of training and feel fully confident applying the patch after just 1-3 times. Healthcare professionals also found that training patients to use the patch was easy.1

Patients follow these simple steps to begin using the CeQur Simplicity 3-day wearable insulin patch*

Fill the patch with a 3-day supply of insulin. CeQur Simplicity holds up to 200 units of rapid-acting insulin*

*Labeled for use with Humalog® U-100 and Novolog® U-100


Use the Inserter to apply the patch to the abdomen for up to three days of wear and injection-free dosing


Remove the Inserter, and the patch is ready to dose.


The CeQur Simplicity wearable insulin patch holds up to 200 units of rapid-acting insulin administered in 2-unit increments.1

Built-in safety features ensure proper dosing and quickly build patient comfort

Two-button safety mechanism prevents accidental dosing. Buttons lock in “squeezed” position when reservoir is empty or cannula is occluded5

Audible and tactile feedback indicates 2-unit delivery5

Water-resistant to a depth of 1 meter for up to 30 minutes5

Our Wearable Insulin Patch Is
Proven Reliable and Effective

CeQur Simplicity is clinically shown to improve glycemic control, which can reduce the risk of long-term health complications.

Week 24
Week 44

After 24 weeks patients decreased their A1C an average of 1.7% and increased time-in-range (TIR) by 50%1

Results were comparable to pens. Consistent A1C <7% supports HEDIS Comprehensive Diabetes Care measure8

The International Consensus on Time-in-range defines clinical target for TIR > 70%, which is evidenced to be the equivalent to an A1C < 7%3

Healthcare Professionals and Patients Prefer CeQur Simplicity

Healthcare professionals prefer the patch to a pen when advancing people with diabetes from basal to basal/bolus insulin management.

We Have You and Your Patients Covered

CeQur Simplicity is covered on most commercial and Medicare Part D insurance plans as a pharmacy benefit. In plans where CeQur Simplicity is covered, two-thirds of patients have a co-pay of $75 or less a month. Individual plans and pharmacy benefits vary by patient, and we at CeQur are here to help you and your patients. Contact the CeQur Care team at 1-888-552-3787.

How to get patients started with the CeQur Simplicity wearable insulin patch
Prescribe CeQur Simplicity 2U patch, 10-pack
Write a Vial of Rapid-Acting Insulin – Labeled for Use with Humalog® U-100 Or Novolog® U-100
The CeQur Simplicity Patient Starter Kit includes:

Two CeQur Simplicity™ patches

Reusable Inserter, only included in the starter kit*

Quick Start Guide

We’re Here to Help You and Your Patients Get Started
Call Us
Email Us

    Select an option*

    Contact reason*

    1. Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B on behalf of the Calibra Study Group. 2019. Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. Diabetes Technology and Therapeutics 21 (5):1-13.
    2. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal R. 2018. Comparing Patch vs. Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. Diabetes 2018 Jul; 67(Supplement 1).
    3. Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 2016. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at the American Diabetes Association’s 76th Scientific Sessions. Abstract 995-P. New Orleans, LA, USA.
    4. Peyrot M, Dreon D, Zraick V, Cross B, Tan MH. 2018. Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch. Diabetes Therapy. 9(1):297–307.
    5. Dreon D, Hannon T, Cross B, Carter B, Mercer N, Nguyen J, Tran A , Melendez P, Morales N, Nelson J, Tan M. 2018. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System. Journal of Diabetes Science and Technology. 12(4):817-827.
    6. Battelino T, Danne T, Bergenstal R, Amiel S, Beck R, Biester T, Bosi E, Buckingham B, Cefalu W, Close K, Cobelli C, Dassau E, DeVries J, Donaghue K, Dovc K, Doyle F, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch I, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy H, Nimri R, Nørgaard K, Parkin C, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer S, Phillip M. 2019. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care Aug 2019, 42 (8) 1593-1603.
    7. Bohannon N, Bergenstal R, Cuddihy R, Kruger D, List S, Massaro E, Molich M, Raskin P, Remtema H, Strowig S, Whitehouse F, Brunelle R, Dreon D, Tan M. 2011. Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study. Diabetes Technology & Therapeutics. 13(10):1031-1037.
    8. 2020 HEDIS Measures summary of changes. HEDIS Measures and Technical Resources 2020  [cited 2020 March 9]; available from:
    9. Peyrot M, et al. Correlates of insulin injection omission. Diabetes Care. 2010; 33(2): p. 242-243 charts, discussion p. 244.
    10. Barry R, Johns DON, Rees B. 2329-PUB: Transitioning T2DM Patients to Basal-Bolus Insulin Leads to Sustainable A1C Improvement. Diabetes, 2019. 68(Supplement 1): p. 2329-PUB. This is a post-hoc analysis done on Bergenstal Trial.

    11. Results from standardized dQ&A patient survey. Data on file at CeQur.
    Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.